Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.

Näytä muut versiot (1)

BACKGROUND: Tumour necrosis factor (TNF)-alpha inhibitors are beneficial for the treatment of rheumatoid arthritis (RA) in terms of reducing the risk of joint damage, improving physical function and improving quality of life. This Cochrane review is an update of a review of the treatment of RA with...

Bibliografiset tiedot
Päätekijät:	Ruiz Garcia, V, Jobanputra, P, Burls, A, Cabello, J, Vela Casasempere, P, Bort-Marti, S, Kynaston-Pearson, F
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	2014

Samankaltaisia teoksia

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Tekijä: Ruiz Garcia, V, et al.
Julkaistu: (2011)

Certolizumab pegol in therapy for rheumatoid arthritis
Tekijä: Galina Viktorovna Lukina, et al.
Julkaistu: (2012-06-01)

Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis
Tekijä: M Connock, et al.
Julkaistu: (2010-10-01)

QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL
Tekijä: Vera Nikolayevna Amirdjanova, et al.
Julkaistu: (2012-10-01)

New aspects of the pharmacotherapy of rheumatoid arthritis: a focus on certolizumab pegol
Tekijä: Evgeniy L'vovich Nasonov, et al.
Julkaistu: (2011-02-01)

Multifocal tuberculosis on certolizumab pegol in a patient followed for rheumatoid arthritis
Tekijä: Emna Hannech, et al.
Julkaistu: (2021-06-01)

New treatment possibilities for rheumatoid arthritis: the Russian experience in using certolizumab pegol
Tekijä: Dmitry Evgenyevich Karateev, et al.
Julkaistu: (2012-04-01)

EFFICACY OF CERTOLIZUMAB PEGOL IN THE TREATMENT OF PSORIATIC ARTHRITIS
Tekijä: T. V. Korotaeva, et al.
Julkaistu: (2015-10-01)

Certolizumab pegol – new option in the treatment of psoriatic arthritis
Tekijä: Maria Majdan, et al.
Julkaistu: (2014-07-01)

Certolizumab pegol in the treatment of spondyloarthritis
Tekijä: Mariusz Korkosz
Julkaistu: (2014-09-01)

Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis
Tekijä: Smolen, JS, et al.
Julkaistu: (2024)

COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM
Tekijä: Purcaru, O, et al.
Julkaistu: (2010)

Prefilled certolizumab pegol (Cimzia&reg;) syringes for self-use in the treatment of rheumatoid arthritis
Tekijä: J Rosa, et al.
Julkaistu: (2010-08-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
Tekijä: Sh. F. Erdes
Julkaistu: (2016-02-01)

Eosinophilic Annular Erythema Due to Certolizumab Pegol Therapy for Rheumatoid Arthritis Post-COVID-19 Vaccine
Tekijä: Andrea Bassi, et al.
Julkaistu: (2023-04-01)

The efficacy of certolizumab pegol in rheumatoid arthritis assessed by gray scale and power Doppler ultrasonography: case reports
Tekijä: José Alexandre Mendonça, et al.
Julkaistu: (2019-02-01)

Exposure–Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
Tekijä: Stéphane Paul, et al.
Julkaistu: (2020-07-01)

Drug Induced Thrombotic Microangiopathy with Certolizumab Pegol
Tekijä: Mehmet Baysal, et al.
Julkaistu: (2018-09-01)

Treatment of pyoderma gangrenosum in pregnancy with certolizumab pegol
Tekijä: Lindsey J. Wanberg, et al.
Julkaistu: (2024-06-01)

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials
Tekijä: Tanaka, Y, et al.
Julkaistu: (2023)

Experience with long-term use of certolizumab pegol (Cimzia)
Tekijä: Karine Arnoldovna Lytkina, et al.
Julkaistu: (2013-10-01)

Experience with long-term use of certolizumab pegol (Cimzia)
Tekijä: Karine Arnoldovna Lytkina, et al.
Julkaistu: (2013-10-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population.
Tekijä: Ian R White, et al.
Julkaistu: (2022-01-01)

A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population
Tekijä: Ian R. White, et al.
Julkaistu: (2022-01-01)

Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
Tekijä: Vivian P. Bykerk, et al.
Julkaistu: (2023-02-01)

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study
Tekijä: Glatt, S, et al.
Julkaistu: (2019)

Quantitation of certolizumab pegol by validated liquid chromatography methods
Tekijä: Clóvis Dervil Appratto Cardoso Júnior, et al.
Julkaistu: (2023-11-01)

Certolizumab pegol in treatment of Crohn's disease with perianal lesions
Tekijä: I.L. Khalif, et al.
Julkaistu: (2018-04-01)

Active axial spondyloarthritis: potential role of certolizumab pegol
Tekijä: Ranatunga S, et al.
Julkaistu: (2014-02-01)

Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów
Tekijä: Piotr Wiland, et al.
Julkaistu: (2011-08-01)

An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
Tekijä: Acosta-Felquer ML, et al.
Julkaistu: (2016-03-01)

CERTOLIZUMAB PEGOL IN THE TREATMENT OF TAKAYASU ARTERITIS: THE FIRST EXPERIENCE AND PROSPECTS
Tekijä: P. I. Novikov, et al.
Julkaistu: (2018-07-01)

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol.
Tekijä: Hazes, J, et al.
Julkaistu: (2010)

Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis
Tekijä: A. Spadaro, et al.
Julkaistu: (2013-07-01)

Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease
Tekijä: Wojciech Blonski, et al.
Julkaistu: (2012-04-01)

Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
Tekijä: O V Knyazev, et al.
Julkaistu: (2018-06-01)

Certolizumab pegol – Tumor necrosis factor inhibitor for refractory uveitis
Tekijä: Yael Sharon, et al.
Julkaistu: (2020-06-01)

Possible relationship between certolizumab pegol and arrhythmias: report of two cases
Tekijä: R. Talotta, et al.
Julkaistu: (2016-09-01)

Effectiveness of Certolizumab Pegol in Treating Rheumatoid Arthritis Patients with Persistent Inflamed Residual Mono- or Oligosynovitis Resistant to Prior TNF-α Inhibitors
Tekijä: Syuichi Koarada, et al.
Julkaistu: (2015-01-01)

Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
Tekijä: Jeffrey R. Curtis, et al.
Julkaistu: (2017-12-01)